Risk of Endophthalmitis After Intravitreal Drug Injection When Topical Antibiotics Are Not Required: The Diabetic Retinopathy Clinical Research Network Laser-Ranibizumab-Triamcinolone Clinical Trials
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To report the incidence of endophthalmitis after intravitreal drug injection by means of a standardized procedure that does not require topical antibiotics, sterile gloves, or a sterile drape. METHODS: Intravitreal injections of preservative-free triamcinolone acetonide or ranibizumab were administered in 2 prospective randomized clinical trials performed by the Diabetic Retinopathy Clinical Research Network. The standardized procedure for these trials requires the use of a topical combination product of povidone-iodine, a sterile lid speculum, and topical anesthetic, but does not require the use of topical antibiotics before, on the day of, or after injection. RESULTS: As of February 23, 2009, a total of 3226 intravitreal injections of ranibizumab and 612 injections of preservative-free triamcinolone had been administered. Topical antibiotics were given on the day of injection in 361 (9.4%) of the 3838 cases, for several days after injection in 813 cases (21.2%), on the day of injection and after injection in 1388 cases (36.2%), and neither on the day of injection nor after injection in 1276 cases (33.3%). Three cases of culture-positive endophthalmitis occurred after ranibizumab injections (0.09%), and no cases occurred after triamcinolone injections. In all 3 cases of endophthalmitis, topical antibiotics were given for several days after the injection but not before injection. CONCLUSIONS: The results suggest that a low rate of endophthalmitis can be achieved by means of a protocol that includes use of topical povidone-iodine, a sterile lid speculum, and topical anesthetic, but does not require topical antibiotics, sterile gloves, or a sterile drape. Trial Registration clinicaltrials.gov Identifiers: NCT00444600 and NCT00445003.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ranibizumab for Neovascular Age-Related Macular Degeneration
Rosenfeld, P. J., Brown, D. M., Heier, J. S., Boyer, D. S., Kaiser, P. K., Chung, C. Y., & Kim, R. Y. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054481 · Cited by 5,886
Pegaptanib for neovascular age-related macular degeneration
Gragoudas, E. S., Adamis, A. P., Cunningham, E. T., Feinsod, M., & Guyer, D. R. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa042760 · Cited by 2,337
Kaiser, P. K., Brown, D. M., Zhang, K., Hudson, H. L., Holz, F. G., Shapiro, H., Schneider, S., & Acharya, N. R. (2007) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2007.08.012 · Cited by 361 · cited 1×
“Despite this, topical antibiotics before intravitreal drug injection have been required in several recent clinical trial protocols.(14-16) Furthermore, recent surveys have suggested that 40% of retina specialists use topical antibiotics before anti– vascular endothelial growth factor intravitreal injections, and 86% u…”
Background
Cited by
2018 Update on Intravitreal Injections: Euretina Expert Consensus Recommendations
Grzybowski, A., Told, R., Sacu, S., Bandello, F., Moisseiev, E., Loewenstein, A., Schmidt-Erfurth, U., & on behalf of the Euretina Board (2018) · Ophthalmologica · doi:10.1159/000486145 · Cited by 297
Complications of intravitreal injections
Sampat, K. M., & Garg, S. J. (2010) · Current Opinion in Ophthalmology · doi:10.1097/icu.0b013e328338679a · Cited by 287
INTRAVITREAL INJECTION TECHNIQUE AND MONITORING: Updated Guidelines of an Expert Panel
Avery, R. L., Bakri, S. J., Blumenkranz, M. S., Brucker, A. J., Cunningham, E. T., D'Amico, D. J., Dugel, P. U., Flynn, H. W., Freund, K. B., Haller, J. A., et al. (2014) · Retina · doi:10.1097/iae.0000000000000399 · Cited by 266
Dossarps, D., Bron, A. M., Koehrer, P., Aho-Glélé, L. S., Creuzot-Garcher, C., Berthon, L., Maftouhi, Q.-E., Bakhti, A., Conrath, J., Le Mer, Y., et al. (2015) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2015.04.013 · Cited by 184
Metadata
- Authors
- Bhavsar, A. R.
- Venue
- Archives of Ophthalmology
- Publisher
- American Medical Association (AMA)
- Published
- 2009-12-14
- Volume
- 127
- Issue
- 12
- Pages
- 1581
- ISSN
- 0003-9950 (ISSN-L)
- OpenAlex
- W2054041974
- Cited by
- 136
- References
- 3
- FWCI
- 10.77
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Risk of Endophthalmitis After Intravitreal Drug Injection When Topical Antibiotics Are Not Required: The Diabetic Retinopathy Clinical Research Network Laser-Ranibizumab-Triamcinolone Clinical Trials. https://app.cochat.ai/papers/10.1001/archophthalmol.2009.304
- The paper
- Bhavsar, A. R. (2009). Risk of Endophthalmitis After Intravitreal Drug Injection When Topical Antibiotics Are Not Required: The Diabetic Retinopathy Clinical Research Network Laser-Ranibizumab-Triamcinolone Clinical Trials. Archives of Ophthalmology. https://doi.org/10.1001/archophthalmol.2009.304
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.